NCT03405168

Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a phase II,single center,prospective, single arm clinical trial. The objective is to evaluate the efficacy and safety of routine therapy plus moxifloxacin in Advanced Breast Cancer whose evaluation is stable disease with a trend of progression.

Detailed description

This is a phase II,single center,prospective, single arm clinical trial. A lot of in vitro and in vivo study demonstrate that quinolones antibiotics can increase anti-tumor effect. The objective is to evaluate the efficacy and safety of routine therapy plus moxifloxacin in Advanced Breast Cancer whose evaluation is stable disease with a trend of progression.

Conditions

• Advanced Breast Cancer
• Antibiotic
• Stable Disease With a Trend of Progression

Interventions

Type	Name	Description
DRUG	Moxifloxacin Hydrochloride 400mg Tablet	Moxifloxacin is oral administration, 400 mg once a day, D1 to D7, 28 days as one cycle.

Timeline

• Start date: 2018-01-01
• Primary completion: 2018-07-30
• Completion: 2018-07-30
• First posted: 2018-01-19
• Last updated: 2018-11-16

Locations

1 site across 1 country: China